Sankarapillai LV, Vijayaraghavareddy P, Nanaiah K, Arpitha GD, Chaitanya PM, Sathishraj R, et al
GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
Thi im ph hp b sung l trc khi n sng hoc trc khi i ng
Importantly, insufficient clearance of damaged mitochondria causes excessive mtDNA, mROS, and cardiolipin externalization and that of other stimulators (e.g., K + efflux), thereby activating the NLRP3 inflammasome (86)
Choosing the time that you're most likely to remember consistently will yield better long-term outcomes than selecting a time based on when side effects might be most or least noticeable
These may indicate serious complications requiring urgent assessment